v3.26.1
Research and Collaboration Arrangements - Summary of Collaboration and License Revenue and Deferred revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue $ 3,781 $ 15 $ 6,828 $ 29  
Collaboration and License Revenue          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue 3,781 15 6,828 29  
Collaboration and License Revenue | Otsuka Pharmaceutical Co., Ltd          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue 3,691 0 6,648 0  
Collaboration and License Revenue | Cystic Fibrosis Foundation          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue 90 $ 15 180 $ 29  
Deferred Revenue          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Deferred revenue 3,315   3,315   $ 1,105
Deferred Revenue | Otsuka Pharmaceutical Co., Ltd          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Deferred revenue 2,390   2,390   0
Deferred Revenue | Cystic Fibrosis Foundation          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Deferred revenue $ 925   $ 925   $ 1,105